FORMULATION AND EVALUATION OF MATRIX TRANSDERMAL PATCHES OF GLIBENCLAMIDE
The present study deals with the formulation and evaluation of transdermal patches of Glibenclamide towards enhance its permeation through the skin and maintain the plasma level concentration. Transdermal patches were prepared by using polymers like Chitosan, HPMC 15cps and EC 20cpsat various concentrations by solvent casting technique employing dibutyl phthalate as plasticizer and iso-propylmyristate as permeation enhancer. The transdermal patches were evaluated for their physico-chemical properties and in-vitro drug release. The transdermal patches were found to be transparent and smooth in texture. Among the formulations studied, at the end of 12th hour, the minimum and maximum in-vitro drug release was observed for the formulations F12 and F4 i.e. 80.012 ± 2.012 % and 98.365±3.012% respectively. The mechanism of drug release was found to be Non-Fickian diffusion controlled. FT-IR studies revealed the integrity of the drug in the formulations.
Keywords: Transdermal Patches, Glibenclamide, Chitosan, HPMC 15cps, EC 20 cps, in-vitro diffusion studies.
2. Baker W and Heller Material Selection for Transdermal Delivery Systems”, In Transdermal Drug Delivery: Developmental Issues and Research Initiatives, J.Hadgraft and R.H.Guys, Eds. Marcel Dekker, Inc., New York 1989 pp. 293-311.
3. Wiechers J. Use of chemical penetration enhancers in Transdermal drug delivery-possibilities and difficulties. Acta pharm. 1992: 4:123.
4. Yamamoto T, Katakabe k, Akiyoshi K, Kan K and Asano T. Topical application of glibenclamide lowers blood glucose levels in rats. Diabetes res. Clin. Pract. 1990; 8:19-22.
5. Al- Khamis K, Davis S.S and Hadgraft J. Microviscosity and drug release from topical gel Formulations. Pharm. Res. 1986; 3:214-217.
6. Anon. Transdermal delivery systems-general drug release standards. Pharmacopeial Forum, 1980; 14:3860-3865.
7. Mayorga P, Puisieux F and Couarraze G. Formulation study of a Transdermal delivery system of primaquine. Int. J. pharm. 1996; 132:71-79.
8. Deo M.R, SantV.P,Parekh S.R, Khopade A.J and Banakar U.V. Proliposome-based Transdermal delivery of levonorgestrel. Jour. Biomat. Appl. 1997; 12:77-88.
9. Yan-yu X, Yun- mei S, Zhi-Peng C and Qi-nerg P Preparation of silymarinproliposomes; A new way to increase oral bioavailability of silymarin in beagle dogs. Int. pharm. 2006; 319:162-168.
10. Crawford R.R and Esmerian O.K. Effect of plasticizers on some physical properties of cellulose acetate phthalate films. J. Pharm. Sci. 1997; 60:312-314.
11. Singh J, Tripathi K.T and SakiaT.R. Effect of penetration enhancers on the invitrotransport of ephedrine through rate skin and human epidermis from matrix based Transdermal formulations. Drug Dev.Ind. Pharm. 1993; 19:1623-1628.
12. Rhaghuram reddy k, Muttalik S and Reddy S. Once – daily sustained- release matrix tablets of nicorandil: formulation and invitroevaluation. AAPS Pharm.Sci.Tech. 2003; 4:4.
13. Shaila L, Pandey S and Udupa N. Design and evaluation of matrix type membrane controlled Transdermal drug delivery system of nicotin suitable for use in smoking cessation. Indian Journ. Pharm. Sci. 2006; 68:179-184
14. Aarti N, Louk A.R.M.P, Russsel.O.P and Richard H.G. Mechanism of oleic acid induced skin permeation enhancement in vivo in humans. Jour control. Release 1995; 37:299-306.
15. Wade A and Weller P.J. Handbook of pharmaceutical Excipients. Washington, DC: American Pharmaceutical Publishing Association 1994; 362-366.
16. Lec S.T, Yac S.H, Kim S.W and Berner B. One way membrane for Transdermal drug delivery system optimization. Int. J Pharm. 1991; 77:231-237.
17. Purna Sai K and Mary Babu, Collagen based dressings: a review, Central Leather Research Institute, Adyar, Chennai, Burns 2000; 26:54-62 pp.
18. Segal, Marian. "Patches, Pumps and Timed Release: New Ways to Deliver Drugs". Food and Drug Administration. Archived from the original on 2007-02-10. Retrieved 2007-02-24.
19. Nachum Z, Shupak A, Gordon CR. "Transdermal scopolamine for prevention of motion sickness: clinical pharmacokinetics and therapeutic applications". Clinical Pharmacokinetics 2006; 45(6):543-66. PMID 16719539.
20. Berner B, John VA. "Pharmacokinetic characterisation of transdermal delivery systems". Clinical pharmacokinetics 1994; 26 (2):121–34. Doi: 10.2165/00003088-199426020-00005.PMID 8162656.
21. Ramkanth S, Alagusundaram M, Gnanaprakash K, Rao M, Saleem M, Paneer K et al. Design and characterization of matrix type transdermal drug delivery system using metoprololtartarate. Int J Adv Pharm Res 2010; 1(1):1-5.
22. Gavali P, Gaikwad A, Radhika PR, Sivakumar T. Design and development of hydroxypropyl methylcellulose (HPMC) based polymeric fi lm of enalapril maleate. Int J Pharm Tech Res 2010; 2(1): 274-82.
23. Praveen M, Rao S, kulkarni S.V, Basavaraj C.S. Formulation and evaluation of tizanidine hydrochloride transdermal patches. Int J Drug Formulation Res 2011; 2(2):298-313.
24. Sanjay dey, ananyamalgope. Preparation of carvedilol transdermal patch and the effect of propylene glycol on permeation. Int J Pha Pharm Sci 2010; 2(1):137-43.
25. Patel N.B., Sonpal R.N., Mohan S, Selvaraj S. Formulation and Evaluation of Iontophoretic Transdermal Delivery of Diltiazem Hydrochloride. Int J Res Pharm Sci 2010; 1(3):338-44.
26. Chien Y.W. Systemic delivery of pharmacologically active molecules across the skin, in: R.L. Juliano (Ed.), Targeted Drug Delivery, Springer- Verlag, Berlin, Heidelberg, New York 1991; p.181-230.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).